Knowledge Content Library
266
Decision Consulting at Eli Lilly and Company: A Journey (History, Evolution and Challenges)
Presented by Charles Persinger (Eli Lilly) at 2011 DAAG Conference in Houston. History and lessons learned from decision consulting within Eli Lilly.
continue to: decisionprofessionals.com
267
Probabilistic Modeling to Support and Facilitate Decision Making in Early Drug Development
Presented by Huybert Groenendaal (EpiX Analytics) at 2011 DAAG Conference in Houston. Overview of use of probabilistic methods to combine wide range of data sources into one decision supporting model.
continue to: decisionprofessionals.com
269
Decision Analysis - Comparison of Pharmaceutical & Upstream Oil
Presented by Vish Viswanathan (Chevron) at 2011 DAAG Conference in Houston. Comparison of the similarities and differences in the use of Decision Analysis in Pharma and Oil & Gas.
continue to: decisionprofessionals.com
256
Walking a Mile in the Shoes of the Decision Maker
Presented by Jay Andersen (Eli Lilly) at 2010 DAAG Conference in Orlando. Discusses importance of understanding the decision maker's perspective, including the Decision Maker's Bill of Rights.
continue to: decisionprofessionals.com
257
Engaging and Retaining DA Practitioners
Presented by Andharia (Merck) at 2010 DAAG Conference in Orlando. Discusses recent history of implementing DA in Merck, what worked and what did not.
continue to: decisionprofessionals.com
258
Transforming the Culture of Strategic Decision-making for a Biotech Organization
Presented by Phil Beccue (Baxter) at 2010 DAAG Conference in Orlando. Discusses practice of DA in Baxter, including training, tools and processes.
continue to: decisionprofessionals.com
249
Improving the process of balancing benefits and risks in approving drugs
Presented by Lawrence D. Phillips (London School of Economics and Political Science) at 2010 DAAG Conference in Orlando. Discussion of benefit risk methods in drug development, and example applied to H1N1 flu vaccine.
continue to: decisionprofessionals.com
250
Quantitative benefit-risk assessment: An analytical framework for a shared understanding of the effects of medicines
Presented by Patrick Ryan (GlaxoSmithKline) at 2010 DAAG Conference in Orlando. Discussion of benefit risk methods in GlaxoSmithKline.
continue to: decisionprofessionals.com
253
Decision Analysis for New Atherosclerosis Drug: Assessing Consistent Probabilities of Success for Drug Development Decision Analysis
Presented by Dave Swank (BristolMyersSquibb) at 2010 DAAG Conference in Orlando. Discussion of probability assessment and the use of sensitivity analysis to look for robustness in assessments.
continue to: decisionprofessionals.com
254
Impact of Manufacturing Strategy On Portfolio Prioritization
Presented by Jerry Ruhland (Baxter) at 2010 DAAG Conference in Orlando. Example of incorporating analysis of manufacturing strategies into portfolio process.
continue to: decisionprofessionals.com
245
An R&D Asset Development Decision Utilizing Lilly’s Quality Decision Process
Presented by Charles Persinger (Eli Lilly) at 2009 DAAG Conference in Indianapolis. Description of Lilly's decision process.
continue to: decisionprofessionals.com
242
Quantitative Benefit-Risk
Presented by James Felli (Eli Lilly) at 2009 DAAG Conference in Indianapolis. Discussion of Lilly's quantitative benefit-risk model based on multi-criteria decision analytic methods.
243
Frame size matters in the public debate on mammography
Presented by Marilyn Metcalf at 2009 DAAG Conference in Indianapolis. Discussion of problem framing and its importance as more patients are drawn into the decision making process.
244
Using the Hippocratic Oath to Provide a Surrogate for Client Utility Functions
Presented by Robert F. Bordley (General Motors) at 2009 DAAG Conference in Indianapolis. Example of how the Hippocratic Oath can be an accessible way to get at utility functions for some clients and patients.
235
Measuring Flow Rates for Projects in an R&D Portfolio: A Case Study
Presented by Jay Andersen (Eli Lilly) at 2009 DAAG Conference in Indianapolis. Incorporation of the speed of project progress with the probability of project success to evaluate the "flow" of projects through the portfolio pipeline.
222
Staying Relevant and Creating Enduring Value
Presented by Greg Parnell (Innovative Decisions) at 2006 DAAG Conference in Baltimore. Keynote address on the top 10 ways to maintain relevance and provide enduring value to your organization.
continue to: decisionprofessionals.com
212
Developing a Portfolio Management System: Values and Tradeoffs
Presented by Phil Beccue (Baxter) and Chris Dalton (Syncopation) at 2006 DAAG Conference in Baltimore. Discussion of development of portfolio process at Baxter, with tradeoffs inherent in designing the process.
continue to: decisionprofessionals.com
214
Following a Lead: Analysis of in-licensing a follow-on oncology compound
Presented by Ajoy Chakrabarti (BristolMyersSquibb) at 2006 DAAG Conference in Baltimore. Discussion of a decision analysis applied to drug licensing problem.
continue to: decisionprofessionals.com
216
Metaphor Mapping
Presented by James Felli (Eli Lilly) at 2006 DAAG Conference in Baltimore. Discussion of the issues with analyzing and communication multi-dimensional data and results, and use of metaphors to simplify into manageable forms.
continue to: decisionprofessionals.com
151
2 Stage Stochastic Programming Approach for R&D Project Selection
Presented by Krishna Chepuri (Johnson & Johnson) at 2005 DAAG Conference in Philadelphia. Application of a 2-stage stochastic integer programming approach to a 2-year portfolio selection problem.
continue to: decisionprofessionals.com